Compare Cronos Group Inc (CRON) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Nike Inc — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while Nike Inc trades at $42.94 (market cap $63.47B). The key difference: Nike Inc is far larger — about 62.2× Cronos Group Inc's market cap, and Nike Inc pays a 3.83% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | NKE | |
|---|---|---|
Market Cap | $1.02B | $63.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $3.27 | $79.24 |
52-Week Low | $1.95 | $40.75 |
Enterprise Value | $203.29M | $65.48B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Nike (NKE) trades at $42.86, down 3.4% on the day, as the stock faces pressure from recent earnings volatility and competitive challenges. The company maintains strong brand recognition with a gross margin of 42.91% and ROE of 22.14%, but revenue declined to $46.31B in 2025 with net income margin compression to 6.7%. Technical indicators show a bullish moving average signal with neutral oscillators, while analyst consensus remains positive with a $50.80 price target representing 18.5% upside potential.
Nike's investment case balances strong profitability metrics against recent revenue headwinds. The stock offers potential upside to analyst targets but faces execution risks in China and EMEA markets, inventory management challenges, and margin pressure from promotional activity. Q2 2026 earnings due June 30 will be critical for validating the company's turnaround strategy and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
